AbbVie receives FDA approval for skin disease treatment.
LocalLabs News Service | Oct 2, 2015

AbbVie receives FDA approval for skin disease treatment

Americans suffering from moderate to severe hidradenitis suppurativa (HS) now have access to an FDA-approved treatment, due to the fact that the FDA has finally approved its drug, which is called Humira, the North Chicago, Illinois-based AbbVie announced today; this announcement comes as the result of 17 years of development and 12 years of clinical trials.

Hidradenitis suppurativa is a chronic inflammatory skin disease characterized by inflamed, painful lesions typically located around the armpits and groin, on the buttocks and under the breasts.

"The symptoms of HS, including inflamed nodules and abscesses, can have a significant impact on patients during their most active years of life," said Alexa Kimball, M.D., M.P.H., director of the Clinical Unit for Research Trials and Outcomes in Skin at Massachusetts General Hospital, professor of dermatology at Harvard Medical School and principal investigator.

Humira was approved by the European Commission in July.

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Labs.

Organizations in this story

+ Abbvie